Cortech inflammation news

CRTQ said it will not resume Phase II trials of Bradycor to treat traumatic brain injury and systemic inflammatory response syndrome (SIRS)/multiple trauma until it finds a corporate partner

CRTQ halted the trials in July after discovering a higher mortality rate in the treated group of patients with SIRS/sepsis. But Joseph Turner, vice president of finance and administration, said the decision to postpone independent development of the drug was purely a financial concern. CRTQ had $27 million in cash as of Aug. 15. ...